33 Poster Discussion - XL092, a multi-targeted inhibitor of MET, VEGFR2, AXL and MER with an optimized pharmacokinetic profile.

Authors :: Hsu, J.
Chong, C.
Goon, L.
Balayan, J.
Wu, S.
Johnson, E.
Lorenzana, G.
Bannen, L.
Nguyen, L.
Scheffold, C.
Lamb, P.
Xu, W.
Yu, P.
Source :: European Journal of Cancer. 2020 Supplement 2, Vol. 138, pS16-S16. 1p.
Publication Year :: 2020

Subjects :: *CONFERENCES & conventions
*IMMUNOTHERAPY
*PROTEIN-tyrosine kinases
*PROTEIN-tyrosine kinase inhibitors
*IMMUNE checkpoint inhibitors
*CHEMICAL inhibitors

Full Text Access

Tools